FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $463,680 | -82.9% | 46,000 | -62.0% | 0.14% | -83.6% |
| Q3 2022 | $2,712,000 | -98.3% | 121,000 | +2989.1% | 0.87% | -47.2% |
| Q2 2022 | $158,000,000 | +2700.9% | 3,917 | -86.0% | 1.65% | +29.6% |
| Q1 2022 | $5,641,000 | +244.4% | 28,000 | 0.0% | 1.27% | +248.5% |
| Q4 2021 | $1,638,000 | -1.3% | 28,000 | 0.0% | 0.36% | -8.8% |
| Q3 2021 | $1,660,000 | – | 28,000 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |